Phase 4 — In-Vivo Animal Studies & Study Design

Phase 4 — In-Vivo Animal Studies & Study Design contains 15 topic pages in Pharmacology.

A compound that has demonstrated potent, selective, and mechanistically coherent activity in vitro must next be evaluated within the physiological complexity of a living organism, where absorption, distribution, metabolism, excretion, immune interaction, and organ-level compensation can all influence — and sometimes completely reverse — the effect predicted from isolated cell or enzyme systems. Phase 4 addresses the ethical and regulatory framework governing animal research in India, the selection of appropriate animal models, dosing methodology, pharmacokinetic study design, and the principal disease models used to demonstrate in-vivo efficacy. In-vivo studies evaluate drug effects within living animal systems, bridging the gap between reductionist in-vitro findings and human clinical trials by generating data on efficacy, pharmacokinetics, biodistribution, and preliminary safety within an intact, homeostatically regulated biological system. In India, every animal study — irrespective of whether it is intended for regulatory submission or purely academic publication — requires prior institutional CPCSEA registration and Institutional Animal Ethics Committee (IAEC) protocol approval before any procedure is performed. The choice of animal model is governed by the physiological similarity of the species to humans for the process under study, practical considerations of cost and handling, and precedent within the relevant regulatory guideline.

Rodent Models

The Wistar rat (150–250 g body weight) is the most widely used general-purpose species for CNS, cardiovascular, metabolic, anti-inflammatory, and analgesic pharmacology, owing to its well-characterised physiology and manageable size. The Sprague-Dawley rat (250–350 g) is particularly favoured for toxicology, reproductive studies, and obesity models, and is the strain preferred by the US-FDA for many regulatory toxicology submissions. The Swiss albino mouse (20–30 g) is the traditional model for acute toxicity (LD50) determination as well as anticancer, infectious disease, and immunology research, while the C57BL/6 mouse (20–25 g), a genetically well-defined inbred strain, is the standard background for diet-induced obesity, neurological, and knockout (genetically modified) models.

Non-Rodent and Alternative Models

The guinea pig (400–700 g) is used in respiratory pharmacology, anaphylaxis, and auditory research owing to its distinctive immune and airway physiology. The rabbit (1.5–3.0 kg) is preferred for cardiovascular studies, ophthalmic irritation testing (the Draize test), and pyrogen testing, given its large ear vessels and sensitivity to pyrogenic substances. Zebrafish (Danio rerio, 0.5–1.5 g) have gained prominence for high-throughput CNS, cardiovascular, toxicological, and teratogenicity screening owing to their transparent embryos and rapid external development. Drosophila (fruit fly, microgram body mass) serves as a genetically tractable model for neuropharmacology, ageing research, and exploratory screening, offering exceptionally rapid generational turnover at minimal cost. The welfare of laboratory animals is not merely an ethical obligation but a direct determinant of data quality, since a stressed, poorly housed, or inadequately cared-for animal introduces uncontrolled physiological variability that can obscure or mimic a genuine drug effect. CPCSEA guidelines, aligned with international standards such as the Guide for the Care and Use of Laboratory Animals, specify housing conditions in detail: ambient temperature is conventionally maintained at 22 ± 2°C, relative humidity at 50–60%, and a 12-hour light/12-hour dark cycle is maintained to preserve normal circadian physiology, which itself influences numerous pharmacological endpoints including drug metabolism and behavioural test performance. Cage density limits (minimum floor area per animal, which varies by species and body weight) prevent overcrowding-related stress and fighting, while environmental enrichment — nesting material, chew items, or shelters — is increasingly required as a matter of good practice, since its absence can itself produce stereotypic behaviours that confound behavioural pharmacology endpoints. Animal husbandry extends to feeding (ad libitum access to a nutritionally standardised pelleted diet, with fasting protocols applied only where specifically required by the experimental design, such as before oral gavage or fasting blood glucose measurement), water (typically provided ad libitum via automated or bottle systems, with water intake itself sometimes serving as a study endpoint), and routine health monitoring, including sentinel-animal screening for pathogens that could otherwise confound immunological or inflammatory endpoints. A dedicated veterinarian, as required under the IAEC structure described above, oversees animal health and is empowered to mandate early euthanasia on welfare grounds independent of the study's scientific objectives, directly operationalising the Refinement principle of the 3Rs. A typical animal pharmacokinetic study proceeds through a defined sequence: dose selection, encompassing both single-dose and multiple-dose designs; selection of the administration route matching the intended clinical route; serial blood sampling, typically spanning 0.25 to 24 hours post-dose to capture the full absorption, distribution, and elimination phases; plasma separation, performed using EDTA anticoagulant and maintained at 4°C to minimise ex-vivo degradation; bioanalysis using a validated chromatographic method, most commonly HPLC or LC-MS/MS, of the kind described in ICH-compliant method validation; non-compartmental analysis (NCA), typically performed using dedicated software such as WinNonlin, to derive parameters including maximum plasma concentration (Cmax), time to maximum concentration (Tmax), area under the curve (AUC), half-life (t½), and clearance; and finally compilation of a formal pharmacokinetic report summarising these derived parameters. A sound experimental design is what allows an in-vivo study to yield a statistically and biologically defensible conclusion from the minimum ethically justifiable number of animals. Three design principles, originally formalised by Ronald Fisher for agricultural field trials but directly applicable to laboratory pharmacology, underlie virtually every well-designed animal study. Randomisation — the random allocation of animals to treatment groups — prevents systematic bias arising from, for example, consistently assigning the first animals removed from a cage (which may be the calmest or most easily handled) to a particular group. Replication — the use of a biologically meaningful number of animals per group, informed by the power calculation introduced in Phase 6 — ensures that the observed effect reflects a genuine population-level phenomenon rather than the idiosyncrasy of one or two individual animals. Blocking (or stratification) — deliberately balancing known sources of variability, such as body weight, litter, or cage, evenly across treatment groups — reduces unexplained variance and increases the statistical power of the eventual analysis. A further critical design consideration is blinding: wherever feasible, the individual performing behavioural scoring, tissue evaluation, or histopathological grading should remain unaware of each animal's treatment group allocation, since even well-intentioned observers show measurable, unconscious bias favouring the expected result when blinding is not employed. Modern reporting guidelines for animal research, most notably the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines, formalise these expectations and are increasingly required by journals as a condition of publication, directly reinforcing the publication and thesis checklist presented in Phase 7. Careful biological sample collection is essential to the validity of downstream pharmacokinetic, biochemical, and histopathological analysis. Blood is typically collected by retro-orbital, tail-vein, or cardiac-puncture techniques depending on volume requirements and whether the procedure is terminal, using appropriate anticoagulants (commonly EDTA) and minimising haemolysis through gentle handling and prompt centrifugation. Organs designated for histopathology or biochemical assay are harvested immediately following euthanasia, weighed (both as absolute organ weight and relative to total body weight, since organ-to-body-weight ratios are a sensitive indicator of toxicity), and either snap-frozen for biochemical analysis or fixed in 10% neutral-buffered formalin for subsequent histopathological processing, a topic examined further in Phase 5. Demonstrating in-vivo efficacy requires a disease model that reproduces the relevant human pathophysiology with sufficient fidelity and reproducibility to allow a genuine drug effect to be distinguished from background biological variability. Over several decades, pharmacologists have developed and validated a large catalogue of such models, spanning virtually every major organ system and disease category. This section presents approximately forty of the most widely used and pedagogically important pharmacological animal models, organised by disease category. For each model, the underlying disease background, the species and strain typically employed, the method and mechanism of induction, the experimental procedure and parameters measured, the standard reference drug, and the principal applications, advantages, limitations, and recent advances are described in theoretical form. Together, these models constitute the practical vocabulary of in-vivo pharmacology and are essential knowledge for GPAT, NIPER, and dissertation-level examination as well as for actual bench research. Phase 4 has addressed the ethical prerequisites (CPCSEA registration, IAEC approval, and the 3Rs), species selection rationale, housing and welfare standards, dosing methodology including human-to-animal dose conversion, pharmacokinetic study design, sound experimental design principles, and the extensive catalogue of validated disease models used to demonstrate pharmacological efficacy in living systems, spanning neurological, cardiovascular, metabolic, inflammatory, infectious, oncological, and dermatological disease areas. A compound showing robust, statistically sound efficacy in these models must next be evaluated for its safety margin — the subject of the toxicology studies presented in Phase 5.